Lentiviral Gene Therapy for Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency: Safety, Efficacy, and 30 Years in the Making
The Journal of Allergy and Clinical Immunology: In Practice · 2026-04 · 14 (4) · 988-991
DOI: 10.1016/j.jaip.2026.02.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-04. Verfasst von Jack Koueik und 1 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Koueik, J., & Seroogy, C. M. (2026). Lentiviral Gene Therapy for Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency: Safety, Efficacy, and 30 Years in the Making. The Journal of Allergy and Clinical Immunology: In Practice, 14(4), 988-991. https://doi.org/10.1016/j.jaip.2026.02.009
Vancouver
Koueik J, Seroogy CM. Lentiviral Gene Therapy for Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency: Safety, Efficacy, and 30 Years in the Making. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(4):988-991. doi:10.1016/j.jaip.2026.02.009
BibTeX
@article{Koueik2026,
author = {Koueik, Jack and Seroogy, Christine M.},
title = {Lentiviral Gene Therapy for Adenosine Deaminase Deficiency-Severe Combined Immunodeficiency: Safety, Efficacy, and 30 Years in the Making},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2026},
volume = {14},
number = {4},
pages = {988--991},
doi = {10.1016/j.jaip.2026.02.009}
}
EUVIMED